136
Views
7
CrossRef citations to date
0
Altmetric
Original Articles

Citalopram for the Prevention of Depression and Its Consequences in HIV-Hepatitis C Coinfected Individuals Initiating Pegylated Interferon/Ribavirin Therapy: A Multicenter Randomized Double-Blind Placebo-Controlled Trial

, , , , , , , , , , , , , , & show all
Pages 161-175 | Published online: 22 Dec 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Mina Borran, Simin Dashti-Khavidaki & Hossein Khalili. (2021) The need for an integrated pharmacological response to the treatment of HIV/AIDS and depression. Expert Opinion on Pharmacotherapy 22:9, pages 1179-1192.
Read now
Renata Fialho, Marco Pereira, Jennifer Rusted & Richard Whale. (2017) Depression in HIV and HCV co-infected patients: a systematic review and meta-analysis. Psychology, Health & Medicine 22:9, pages 1089-1104.
Read now

Articles from other publishers (5)

Hans-Peter KapfhammerHans-Peter Kapfhammer. 2022. Depression, Angst, traumatischer Stress und internistische Erkrankungen. Depression, Angst, traumatischer Stress und internistische Erkrankungen 475 542 .
David M. Taylor, Thomas R. E. Barnes & Allan H. Young. 2021. The Maudsley Prescribing Guidelines in Psychiatry. The Maudsley Prescribing Guidelines in Psychiatry 777 830 .
Saeed Farooq, Surrendra P Singh, Danielle Burke, Farooq Naeem & Muhammad Ayub. (2020) Pharmacological interventions for prevention of depression in high risk conditions: Systematic review and meta-analysis.. Journal of Affective Disorders 269, pages 58-69.
Crossref
Montserrat Masip, Laura Tuneu, Neus Pagès, Xavier Torras, Adolfo Gallego, Josep Maria Guardiola, María José Faus & Maria Antònia Mangues. (2015) Prevalence and detection of neuropsychiatric adverse effects during hepatitis C treatment. International Journal of Clinical Pharmacy 37:6, pages 1143-1151.
Crossref
Z. Younossi & L. Henry. (2015) Systematic review: patient-reported outcomes in chronic hepatitis C - the impact of liver disease and new treatment regimens. Alimentary Pharmacology & Therapeutics 41:6, pages 497-520.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.